Recently, the HIF-2-selective inhibitor Belzutifan has been approved for the treatment of renal cell carcinoma in patients with von Hippel-Lindau syndrome,74 but the studies summarized here suggest this drug will not be effective in blocking hypoxia-induced BCSC specification, which appears to be controlled exclusively by HIF-1. The gene discussed is HIF1A; the disease is renal cell carcinoma.